Congress trade2 different filers disclosed VRTX within 90 days. Disclosed 4 days after the transaction; reported as an official range, not an exact amount.
Loading…
Traded Jan 7, 2026 · Filed Jan 9, 2026
Vertex Pharmaceuticals's Chief Reg. & Quality Off. sold $2.14M of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,137,455
Shares × reported transaction price
65 days after results of Nov 3, 2025, 36 days before results of Feb 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $484.15 on Jan 7, 2026, 32% above its 52-week low and 6% below its high, after a 13% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $513.76 (Mar 17, 2025), 80% of the way up, from 250 adjusted closes. 30 trading days earlier: $426.76 on Nov 21, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -4.0% | -2.5% | -1.5% |
| 30 days | +0.1% | -0.5% | +0.6% |
| 90 days | -4.5% | -1.3% | -3.2% |
| 180 days | +4.3% | +7.8% | -3.5% |
Past results only. Not a forecast.
2 different filers disclosed VRTX within 90 days. Disclosed 4 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.